Clinical Trial Update: Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) [Phase 3]

View source ↗

Summary

Phase 3 trial update for REWIND evaluating a weekly incretin in patients with type 2 diabetes and cardiovascular disease; completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Eli Lilly and Company | Conditions: Cardiovascular Disease, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2019-10-08